The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma
Open accessAbstract
Purpose: CXCR4 receptor and its unique ligand, the CXCL12 chemokine, have been recently implicated in cancer metastasis. Evidence about the role of CXCR4/CXCL12 axis has been reported in several cancers including melanoma. Our goal was to investigate if CXCR4 expression has a prognostic value in malignant melanoma. Experimental Design: Immunohistochemical expression of CXCR4 was evaluated on 71 specimens of primary cutaneous melanoma with a Breslow tumor thickness of >1 mm after radical resection. Associations between baseline patient features and tumors were analyzed by χ2 test. The prognostic value of CXCR4 expression was evaluated by univariate and multivariate analyses adjusted by age, sex, Breslow tumor thickness, presence of ulceration, and sentinel lymph node metastases. Results: CXCR4 expression was detected in 31 of 71 (43.6%) primary cutaneous melanomas. Membrane or cytoplasmic staining for CXCR4 protein was absent in 56% of the tumors. The positive cases were divided into three score classes according to their staining: low in 15 cases (21%), moderate in 10 (14%), and high in 6 (8%). After a median follow-up of 38 months, 26 patients progressed (16 of 26 expressed CXCR4) and 19 died (12 of 19 expressed CXCR4). The CXCR4 expression on tumor cells was correlated with an unfavorable prognosis with a median disease-free and overall survival of 22 and 35 months, respectively. The hazard ratios of relapse and death, compared with patients with CXCR4-negative tumors, were 2.5 (95% confidence interval, 1.2-6.1) and 3.1 (95% confidence interval, 1.1-7.2), respectively. Median time-to-event (progression and survival) was not reached in patients with CXCR4-negative tumors. In the multivariate analysis, CXCR4 expression, presence of ulceration, and sentinel lymph node status emerged as independent prognostic factors. Conclusions: This article provides the first evidence that CXCR4 expression could be an independent and powerful prognostic marker in primary cutaneous malignant melanomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 994
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
Rubin, J. B., Kung, A. L., Klein, R. S., Chan, J. A., Sun, Y., Schmidt, K., Kieran, M. W., Luster, A. D., & Segal, R. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235846100 · Cited by 615
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton, C. J., Wilson, J. L., Scott, K. A., Stamp, G., Wilbanks, G. D., Fricker, S. P., Bridger, G. J., & Balkwill, F. R. (2002) · PubMed · Cited by 471
Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States
Jemal, A., Devesa, S. S., Hartge, P., & Tucker, M. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.678 · Cited by 449
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Zeelenberg, I. S., Stalle, L. R.-V., & Roos, E. (2003) · PubMed · Cited by 430
Bachelder, R. E., Wendt, M. A., & Mercurio, A. M. (2002) · PubMed · Cited by 424
Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J., Tsuji, S., Nakajima, S., Kawaguchi, M., Kobayashi, H., Doi, R., Hori, T., et al. (2000) · PubMed · Cited by 424
Cited by
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., & Wang, J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9256-x · Cited by 727
The Intricate Role of CXCR4 in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 672
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., de Vries, E. G. E., & Walenkamp, A. M. E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 635
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
Metadata
- Authors
- Scala, S., Ottaiano, A., Ascierto, P. A., Cavalli, M., Simeone, E., Giuliano, P., Napolitano, M., Franco, R., Botti, G., & Castello, G.
- Venue
- Clinical Cancer Research
- Published
- 2005-03-01
- Volume
- 11
- Issue
- 5
- Pages
- 1835-1841
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2134603265
- Cited by
- 280
- References
- 41
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1887
- The paper
- Scala, S., Ottaiano, A., Ascierto, P. A., Cavalli, M., Simeone, E., Giuliano, P., Napolitano, M., Franco, R., Botti, G., & Castello, G. (2005). Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1887
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.